News

U.Va. biolab seeks to catalyze region’s growth

Thomas Barker says his seed-stage startup wants to find “modern, modular, functional lab space” to allow the company he co-founded, Vasarya Therapeutics, to be “very efficient and optimal on our research enterprise.”

But good lab space is hard to come by in Charlottesville, and what exists is spread around, “so you don’t necessarily get the impact of having other startup and tech companies in your space being in close proximity,” adds Barker, who is also Vasarya’s chief scientific officer.

CvilleBioHub hopes to address those problems by creating CvilleBioLab, an accelerator where early-stage companies can spend a year or two performing research while also being mentored by business leaders and advisers who can help “de-risk” the startup process, including navigating issues like intellectual property protection, says Nikki Hastings, executive director and co-founder of the nonprofit. Founded in 2016, CvilleBioHub advocates for and works to build the area’s biotech community.

In March, the organization received a $100,000 GO Virginia grant to support planning for CvilleBioLab. While there’s no timeline for site selection, CvilleBioHub’s real estate partner, Rockville, Maryland-based Scheer Partners, is searching for an existing building to convert. “Ideally, we’d like 15,000 to 20,000 square feet, although we could get started with 5,000,” Hastings says.

Depending on the size, Hastings, the biotech track director at the University of Virginia’s McIntire School of Commerce, estimates spending around $3 million for infrastructure and equipment, with operating costs for staffing, maintenance, and overhead running between $500,000 and $1 million annually. Funding is still being determined, Hastings says.

The facility will include a wet lab and equipment including refrigerators, ultra-low-temperature freezers for DNA samples and other biological material, incubators, cell culture and DNA analysis tools, and basic lab equipment like microscopes.

The lab’s buildout is expected to take about a year. Companies will apply for a spot, with six to eight startups sharing the facility, though Hastings says CvilleBioHub will use part of the planning grant to “more definitively” determine programming during the summer. A lab director and entrepreneur advisory team will support occupants.

Charlottesville-area researchers who want to spin their work into a startup would benefit from having a formal incubator, says Renna Nouwairi, a Ph.D. candidate in bioanalytical chemistry at U.Va. “It would be a shame for our city and local economy to miss out on opportunities because a startup-friendly infrastructure is not in place.”

 

Learn more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and